氯雷他定联合孟鲁司特钠对变应性鼻炎患者血清ICAM-1 ECP EOS CSF的影响研究

doi:10.3969/j.issn.1006-6233.2019.02.028

摘要
图/表
参考文献
相关文章 (7)

全文: PDF (1268 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:探讨氯雷他定联合孟鲁司特钠对变应性鼻炎患者血清ICAM-1、ECP、EOS、CSF的影响。方法:104例变应性鼻炎患者均来自于2013年8月至2015年10月期间的临床病例,通过简单随机分组法分为对照组和实验组,每组52例。对照组接受氯雷他定口服治疗,实验组在对照组的基础上加以联合孟鲁司特钠治疗。比较两组临床疗效,治疗前后血清细胞间黏附分子-1(Intercellular cell adhesion molecule-1, ICAM-1)、嗜酸细胞阳离子蛋白(Eosinophil cationic protein,ECP)、嗜酸性粒细胞百分率(Eosinophil count,EOS)、脑脊液(cerebrospinal fluid,CSF)水平、各项鼻部症状 VAS 评分及不良反应的发生情况。结果:治疗后,实验组临床疗效有效率(90.38%)高于对照组(80.77%),差异有统计学意义(P<0.05)。治疗前两组血清ICAM-1、ECP、EOS、CSF水平相比较,无明显差异(P<0.05),治疗后,实验组明显低于对照组[(6.69±2.08)VS(7.86±2.69)、(374.58±69.83)VS(468.46±80.53)、(3.02±0.88)VS(3.91±0.89)、(16.69±3.47)VS(29.58±5.73)];治疗后两组各项鼻部症状VAS评分均显著下降,实验组明显低于对照组,两组不良反应比较无差异(P>0.05)。结论:氯雷他定联合孟鲁司特钠对变应性鼻炎患者的治疗效果肯定,能够降低患者血清ICAM-1、ECP、EOS、CSF水平,改善临床症状,值得临床推广运用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘怡君
	曾邦兵
	曾浪

关键词 ：变应性鼻炎, 氯雷他定, 孟鲁司特钠

Abstract：Objective: To investigate the effects of loratadine and montelukast on serum levels of ICAM-1, ECP, EOS and CSF in patients with allergic rhinitis. Methods: 104 cases of allergic rhinitis patients were from August 2013 to October to 2015 period in our hospital clinical cases, by drawing lots were randomly divided into the control group and the experimental group, 52 cases in each group. The control group received oral loratadine treatment, and the experimental group was treated with montelukast on the basis of the control group. The clinical efficacy, the levels of serum ICAM-1, ECP, EOS, CSF, nasal symptoms, VAS score and adverse reactions before and after treatment were compared between the two groups. Results: After treatment, the clinical efficacy of the experimental group (90.38%) was higher than that of the control group (80.77%), and the difference was statistically significant (P<0.05). There was no significant difference in serum ICAM-1, ECP, EOS and CSF levels between the two groups before treatment (P<0.05). After treatment, the VAS scores of the experimental group were significantly lower than those of the control group [(6.69 +2.08) VS (7.86 +2.69), (374.58 +69.83) VS (468.46 +80.53), (3.02 +0.88) VS (3.91 +0.89), (16.69 +3.47) VS (29.58 +5.73)]. After treatment, the nasal symptoms of the two groups were significantly lower than those of the control group. The adverse reactions in the experimental group were significantly lower than those in the control group, and there was no difference between the two groups (P>0.05). Conclusion: Loratadine combined with montelukast sodium has a definite therapeutic effect on allergic rhinitis. It can reduce the levels of serum ICAM-1, ECP, EOS and CSF, improve clinical symptoms, and is worthy of clinical application.

Key words： Allergic rhinitis Loratadine Montelukast

基金资助:四川省科技计划项目,(编号:20140226)

引用本文:

刘怡君, 曾邦兵, 曾浪. 氯雷他定联合孟鲁司特钠对变应性鼻炎患者血清ICAM-1 ECP EOS CSF的影响研究[J]. 河北医学, 2019, 25(2): 280-283.
LIU Yijun, ZENG Bangbing, ZENG Lang. Effect of Loratadine combined with Montelukast Sodium on Serum ICAM-1 ECP EOS and CSF in Patients with Allergic Rhinitis. HeBei Med, 2019, 25(2): 280-283.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2019.02.028 或 http://www.hbyxzzs.cn/CN/Y2019/V25/I2/280